KR102162619B1 - 유기 화합물 - Google Patents

유기 화합물 Download PDF

Info

Publication number
KR102162619B1
KR102162619B1 KR1020157004813A KR20157004813A KR102162619B1 KR 102162619 B1 KR102162619 B1 KR 102162619B1 KR 1020157004813 A KR1020157004813 A KR 1020157004813A KR 20157004813 A KR20157004813 A KR 20157004813A KR 102162619 B1 KR102162619 B1 KR 102162619B1
Authority
KR
South Korea
Prior art keywords
group
compound
formula
alkyl
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020157004813A
Other languages
English (en)
Korean (ko)
Other versions
KR20150073942A (ko
Inventor
벤쟈민 제이슨 캄튼
콜린 말콤 헤이먼
이안 프란시스 헐먼스
데이빗 사무엘 라슨
개빈 프랭크 페인터
레건 제임스 앤더슨
Original Assignee
빅토리아 링크 엘티디
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 빅토리아 링크 엘티디 filed Critical 빅토리아 링크 엘티디
Publication of KR20150073942A publication Critical patent/KR20150073942A/ko
Application granted granted Critical
Publication of KR102162619B1 publication Critical patent/KR102162619B1/ko
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/02—Acyclic radicals, not substituted by cyclic structures
    • C07H15/04—Acyclic radicals, not substituted by cyclic structures attached to an oxygen atom of the saccharide radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/02—Acyclic radicals, not substituted by cyclic structures
    • C07H15/04—Acyclic radicals, not substituted by cyclic structures attached to an oxygen atom of the saccharide radical
    • C07H15/06—Acyclic radicals, not substituted by cyclic structures attached to an oxygen atom of the saccharide radical being a hydroxyalkyl group esterified by a fatty acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Otolaryngology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Endocrinology (AREA)
  • Transplantation (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
KR1020157004813A 2012-07-26 2013-07-26 유기 화합물 Expired - Fee Related KR102162619B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
NZ60147312 2012-07-26
NZ601473 2012-07-26
PCT/NZ2013/000133 WO2014017928A1 (en) 2012-07-26 2013-07-26 Organic compounds

Publications (2)

Publication Number Publication Date
KR20150073942A KR20150073942A (ko) 2015-07-01
KR102162619B1 true KR102162619B1 (ko) 2020-10-08

Family

ID=49997620

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020157004813A Expired - Fee Related KR102162619B1 (ko) 2012-07-26 2013-07-26 유기 화합물

Country Status (9)

Country Link
US (1) US9586985B2 (cg-RX-API-DMAC7.html)
EP (1) EP2877481B1 (cg-RX-API-DMAC7.html)
JP (1) JP6528029B2 (cg-RX-API-DMAC7.html)
KR (1) KR102162619B1 (cg-RX-API-DMAC7.html)
CN (1) CN104736550B (cg-RX-API-DMAC7.html)
AU (1) AU2013293646B2 (cg-RX-API-DMAC7.html)
CA (1) CA2880191C (cg-RX-API-DMAC7.html)
IN (1) IN2015KN00492A (cg-RX-API-DMAC7.html)
WO (1) WO2014017928A1 (cg-RX-API-DMAC7.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6548579B2 (ja) * 2012-12-06 2019-07-24 ヴィクトリア リンク リミテッド コンジュゲート化合物
US9717790B2 (en) * 2013-06-10 2017-08-01 Victoria Link Limited Sphingoglycolipid analogues
US10046046B2 (en) 2014-06-05 2018-08-14 Victoria Link Limited Amino sphingoglycolipid analogues
JP6453033B2 (ja) * 2014-10-22 2019-01-16 国立大学法人北海道大学 糖スフィンゴシン及びスフィンゴ塩基の製造方法
US9394312B1 (en) * 2015-06-14 2016-07-19 Mark Quang Nguyen Ibrutinib prodrugs, pharmaceutical compositions thereof, and methods of use
EP3374028B1 (en) * 2015-11-13 2021-05-26 La Jolla Institute for Allergy and Immunology Sphingamide compounds and methods for binding inkt cells
EP3434684A4 (en) * 2016-03-22 2019-11-27 Keio University COMPOUND OR SALT THEREOF, NATURAL KILLER T CELL ACTIVATOR AND PHARMACEUTICAL COMPOSITION
WO2019122050A1 (en) 2017-12-22 2019-06-27 Isa Pharmaceuticals B.V. Methods of immunization
JP2024510435A (ja) 2021-03-18 2024-03-07 シージェン インコーポレイテッド 生体活性化合物の内部移行複合体からの選択的薬物放出

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005263797A (ja) 2004-02-19 2005-09-29 Kibun Food Chemifa Co Ltd NKT細胞活性化用組成物、IL−4産生促進用組成物、IFN−γ産生促進用組成物、樹状細胞活性化用組成物、IL−12産生促進用組成物、IL−10産生促進用組成物、NK細胞活性化用組成物、抗腫瘍作用組成物、抗アレルギー作用組成物、感染抵抗性増強用組成物、抗ウイルス作用組成物、IL−6産生促進用組成物、NO産出促進用組成物
JP2008525495A (ja) 2004-12-28 2008-07-17 ザ ロックフェラー ユニバーシティ Nkt細胞に対する抗原としての糖脂質及びその類似体
JP2011503034A (ja) 2007-11-07 2011-01-27 ウィッティセル 免疫反応の増加、及び抗原及び/又は薬物結合による標的化

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4410913B2 (ja) * 2000-06-12 2010-02-10 壽製薬株式会社 新規糖脂質誘導体の製造方法
WO2004094444A1 (en) 2003-03-20 2004-11-04 Brigham Young University 6'-amino-6'-deoxygalactosylceramides
US20060024691A1 (en) * 2004-03-25 2006-02-02 Buck Institute For Age Research Novel pathways in the etiology of cancer
AU2005280163B2 (en) * 2004-08-27 2011-11-24 Albert Einstein College Of Medicine, Inc. Ceramide derivatives as modulators of immunity and autoimmunity
US7923013B2 (en) 2004-12-28 2011-04-12 The Rockefeller University Glycolipids and analogues thereof as antigens for NKT cells
WO2007035717A2 (en) * 2005-09-19 2007-03-29 The Rockefeller University Glycolipids and analogues thereof as antigents for nk t cells
WO2008047174A1 (en) * 2006-10-18 2008-04-24 Centre National De La Recherche Scientifique Alpha-galactosylceramide analogs, their methods of manufacture, intermediate compounds useful in these methods, and pharmaceutical compositions containing them
US20080133801A1 (en) * 2006-12-04 2008-06-05 Aten International Co., Ltd. Keyboard-video-mouse switch system for switching between computers having a plurality of video sources each and switching method thereof
US7731851B2 (en) 2007-04-12 2010-06-08 Novozymes Biologicals, Inc. Waste water treatment
US9220767B2 (en) * 2008-10-08 2015-12-29 Abivax Vaccine composition for use against influenza

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005263797A (ja) 2004-02-19 2005-09-29 Kibun Food Chemifa Co Ltd NKT細胞活性化用組成物、IL−4産生促進用組成物、IFN−γ産生促進用組成物、樹状細胞活性化用組成物、IL−12産生促進用組成物、IL−10産生促進用組成物、NK細胞活性化用組成物、抗腫瘍作用組成物、抗アレルギー作用組成物、感染抵抗性増強用組成物、抗ウイルス作用組成物、IL−6産生促進用組成物、NO産出促進用組成物
JP2008525495A (ja) 2004-12-28 2008-07-17 ザ ロックフェラー ユニバーシティ Nkt細胞に対する抗原としての糖脂質及びその類似体
JP2011503034A (ja) 2007-11-07 2011-01-27 ウィッティセル 免疫反応の増加、及び抗原及び/又は薬物結合による標的化

Also Published As

Publication number Publication date
JP2015522656A (ja) 2015-08-06
US9586985B2 (en) 2017-03-07
CA2880191C (en) 2021-04-20
KR20150073942A (ko) 2015-07-01
WO2014017928A1 (en) 2014-01-30
CA2880191A1 (en) 2014-01-30
CN104736550B (zh) 2017-12-29
EP2877481A4 (en) 2016-04-06
AU2013293646A1 (en) 2015-03-12
US20150191503A1 (en) 2015-07-09
EP2877481A1 (en) 2015-06-03
IN2015KN00492A (cg-RX-API-DMAC7.html) 2015-07-17
AU2013293646B2 (en) 2017-10-19
CN104736550A (zh) 2015-06-24
JP6528029B2 (ja) 2019-06-12
EP2877481B1 (en) 2019-11-27

Similar Documents

Publication Publication Date Title
EP2877481B1 (en) Organic compounds
EP2661440B1 (en) Method for the preparation of glycosphingolipids
EP2928902B1 (en) Conjugate compounds
JP5669215B2 (ja) 新規合成糖脂質およびその用途
WO2015187040A1 (en) Amino sphingoglycolipid analogues
US9717790B2 (en) Sphingoglycolipid analogues
NZ613614B2 (en) Sphingoglycolipid compounds and uses

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R13-asn-PN2301

St.27 status event code: A-3-3-R10-R11-asn-PN2301

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

P22-X000 Classification modified

St.27 status event code: A-2-2-P10-P22-nap-X000

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

N231 Notification of change of applicant
PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R13-asn-PN2301

St.27 status event code: A-3-3-R10-R11-asn-PN2301

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

R17-X000 Change to representative recorded

St.27 status event code: A-5-5-R10-R17-oth-X000

PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20230929

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20230929